Dr. Hahn Discusses Abiraterone Versus Docetaxel in Prostate Cancer

Andy Hahn, MD
Published: Tuesday, Jun 26, 2018



Andy Hahn, MD, resident, University of Utah School of Medicine, discusses abiraterone acetate (Zytiga) versus docetaxel in the treatment of patients with prostate cancer.

Although there has not yet been a head-to-head trial comparing androgen deprivation therapy (ADT) plus abiraterone versus ADT plus docetaxel, STAMPEDE reported out data with these 2 combinations simultaneously. Data from this trial showed that when comparing abiraterone with docetaxel, there was no significant difference in overall survival or metastasis-free survival. There was a trend in favor of abiraterone regarding progression-free survival and failure-free survival, but these were surrogate endpoints, Hahn says.

The PEACE-1 trial, which will read out in the next few years, may offer an answer to the question of abiraterone versus docetaxel, Hahn says. This trial is evaluating a variety of combinations, including a head-to-head comparison of ADT plus docetaxel versus ADT plus abiraterone.


Andy Hahn, MD, resident, University of Utah School of Medicine, discusses abiraterone acetate (Zytiga) versus docetaxel in the treatment of patients with prostate cancer.

Although there has not yet been a head-to-head trial comparing androgen deprivation therapy (ADT) plus abiraterone versus ADT plus docetaxel, STAMPEDE reported out data with these 2 combinations simultaneously. Data from this trial showed that when comparing abiraterone with docetaxel, there was no significant difference in overall survival or metastasis-free survival. There was a trend in favor of abiraterone regarding progression-free survival and failure-free survival, but these were surrogate endpoints, Hahn says.

The PEACE-1 trial, which will read out in the next few years, may offer an answer to the question of abiraterone versus docetaxel, Hahn says. This trial is evaluating a variety of combinations, including a head-to-head comparison of ADT plus docetaxel versus ADT plus abiraterone.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x